Immunotherapies in neuromyelitis optica spectrum disorder

• Verfasst von: Stellmann, Jan-Patrick [VerfasserIn]
• Verfasst von: Wildemann, Brigitte [VerfasserIn]
• Verfasst von: Jarius, Sven [VerfasserIn]
• Titel: Immunotherapies in neuromyelitis optica spectrum disorder
• Titelzusatz: efficacy and predictors of response
• Verf.angabe: Jan-Patrick Stellmann, Markus Krumbholz, Tim Friede, Anna Gahlen, Nadja Borisow, Katrin Fischer, Kerstin Hellwig, Florence Pache, Klemens Ruprecht, Joachim Havla, Tania Kümpfel, Orhan Aktas, Hans-Peter Hartung, Marius Ringelstein, Christian Geis, Christoph Kleinschnitz, Achim Berthele, Bernhard Hemmer, Klemens Angstwurm, Kim Lea Young, Simon Schuster, Martin Stangel, Florian Lauda, Hayrettin Tumani, Christoph Mayer, Lena Zeltner, Ulf Ziemann, Ralf Andreas Linker, Matthias Schwab, Martin Marziniak, Florian Then Bergh, Ulrich Hofstadt-van Oy, Oliver Neuhaus, Uwe Zettl, Jürgen Faiss, Brigitte Wildemann, Friedemann Paul, Sven Jarius, Corinna Trebst, Ingo Kleiter, on behalf of NEMOS (Neuromyelitis Optica Study Group)
• E-Jahr: 2017
• Jahr: June 2, 2017
• Umfang: 9 S.
• Teil: volume:88
• Teil: year:2017
• Teil: number:8
• Teil: pages:639-647
• Teil: extent:9
• Fussnoten: Published online first 2 June 2017 ; Gesehen am 19.09.2018
• Titel Quelle: Enthalten in: Journal of neurology, neurosurgery, and psychiatry
• Ort Quelle: London : BMJ Publishing Group, 1944
• Jahr Quelle: 2017
• Band/Heft Quelle: 88(2017), 8, Seite 639-647
• ISSN Quelle: 1468-330X
• DOI: doi:10.1136/jnnp-2017-315603
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Aquaporin-4 antibody
• Sach-SW: Azathioprine
• Sach-SW: Neuromyelitis optica spectrum disorder
• Sach-SW: Rituximab
• Sach-SW: Therapy
• K10plus-PPN: 1581098510

Abstract

Objective: To analyse predictors for relapses and number of attacks under different immunotherapies in patients with neuromyelitis optica spectrum disorder (NMOSD). Design: This is a retrospective cohort study conducted in neurology departments at 21 regional and university hospitals in Germany. Eligible participants were patients with aquaporin-4-antibody-positive or aquaporin-4-antibody-negative NMOSD. Main outcome measures were HRs from Cox proportional hazard regression models adjusted for centre effects, important prognostic factors and repeated treatment episodes. Results: 265 treatment episodes with a mean duration of 442 days (total of 321 treatment years) in 144 patients (mean age at first attack: 40.9 years, 82.6% female, 86.1% aquaporin-4-antibody-positive) were analysed. 191 attacks occurred during any of the treatments (annual relapse rate=0.60). The most common treatments were rituximab (n=77, 111 patient-years), azathioprine (n=52, 68 patient-years), interferon-β (n=32, 61 patient-years), mitoxantrone (n=34, 32.1 patient-years) and glatiramer acetate (n=17, 10 patient-years). Azathioprine (HR=0.4, 95% CI 0.3 to 0.7, p=0.001) and rituximab (HR=0.6, 95% CI 0.4 to 1.0, p=0.034) reduced the attack risk compared with interferon-β, whereas mitoxantrone and glatiramer acetate did not. Patients who were aquaporin-4-antibody-positive had a higher risk of attacks (HR=2.5, 95% CI 1.3 to 5.1, p=0.009). Every decade of age was associated with a lower risk for attacks (HR=0.8, 95% CI 0.7 to 1.0, p=0.039). A previous attack under the same treatment tended to be predictive for further attacks (HR=1.5, 95% CI 1.0 to 2.4, p=0.065). Conclusions: Age, antibody status and possibly previous attacks predict further attacks in patients treated for NMOSD. Azathioprine and rituximab are superior to interferon-β.